Despite short-term stock outperformance, fundamental metrics are concerning: quarterly revenue projected down 39% YoY, full-year revenue down 68% YoY, negative EPS of -$0.46, and declining analyst estimates (-7.86% over past month). The Zacks Rank of #3 (Hold) and the industry's bottom 35% ranking further support a negative outlook.
Despite recent positive price momentum (+14.25% monthly), Novavax faces significant fundamental challenges including projected negative EPS (-$0.22 quarterly, -$0.47 annually), substantial revenue declines (39-68% year-over-year), and downward analyst estimate revisions (-10.12% in 30 days). The Hold rating reflects these deteriorating business metrics.
Stock up 13.16% on Friday; Q1 sales of $139.51M beat analyst estimates of $78.32M; year-to-date gains of 38% outpacing S&P 500's 7.5% gain
Articles that tag NVAX but are mainly about other companies.
Mentioned as competitor in COVID-19 vaccine market (Nuvaxovid); no direct news or impact discussed in article.
One of four dominant COVID-19 vaccine companies mentioned; article notes that even successful vaccine makers don't guarantee market-beating returns for investors.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
